References
- Hagemeister F. B., Fuller L. M., Sullivan J. A., et al. Treatment of patients with stages I and II nonme-diastinal Hodgkin's disease. Cancer 1982; 50: 2307–2313
- Longo D. L., Russo Aa., Duffey P. L., et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. Journal of Clinical Oncology 1991; 9: 227–235
- Hagemeister F. B., Fuller L. M., Sullivan J. A., et al. Treatment of stage I and II mediastinal Hodgkin's disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology 1981; 141: 783–789
- Fuller L. M., Hagemeister F. B., North L. B., et al. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: Preliminary results. International Journal Radiation Oncology, Biology, Physics 1988; 14: 683–692
- Rogers R. W., Fuller L. M., Hagemeister F. B., et al. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer 1981; 47: 2196–2203
- Valagussa P., Santoro A., Boracchi P., et al. 9-year results of two randomized studies with MOPP and ABVD in Hodgkin's disease (HD): Multiple regression analysis. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989; 8: 250
- Viviani S., Santoro A., Ragni G., et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP and ABVD. European Journal of Cancer and Clinical Oncology 1985; 21: 601–605
- Silver R. T., Case D. C., Wheeler R. H., et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. Journal of Clinical Oncology 1991; 9: 754–761
- Lister T. A., Crowther D., Sutcliffe S. B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. J. Clin. Oncol. 1989; 7: 1630–1636
- Iqbal Z. M., Kohn K. W., Ewig A. G., Fornace A. J. Single strand scission and repair of DNA in mammalian cells by bleomycin. Cancer Research 1976; 36: 3834–3838
- Paterson M. C., Smith P. J. Ataxia telangiec-tasia: an inherited human disorder involving hypersensitivity to ionizing radiation and related DNA-damaging chemicals. Annual Review Genetics 1979; 13: 291–318
- Setlow R. B., Reogan J. D., German J., Carrier W. L. Evidence that xeroderma pigmentosum cells do not perform the first step in the repair of ultraviolet damage to their DNA. In Proceedings of the National Academy Sciences (USA) 1969; 64: 1035–1041
- Schantz S. P., Splitz M. R., Hsu T. C. Mu-tagen sensitivity in patients with head and neck cancers: A biologic marker for risk of multiple primary malignancies. Journal of the National Cancer Institute 1990; 82: 1773–1775
- Cherry L. M., Hsu T. C. Bleomycin-induced chromosome damage in lymphocytes of medullary thyroid carcinoma patients and their family members. Anticancer Research 1983; 3: 367–372